
Last update at 2026-03-12T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Value Stocks with Questionable Fundamentals
Mon 05 May 25, 04:35 AM1 Safe-and-Steady Stock to Own for Decades and 2 to Avoid
Tue 29 Apr 25, 01:02 PM3 Russell 2000 Stocks with Bad Fundamentals
Wed 16 Apr 25, 01:02 PMCencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Tue 11 Mar 25, 01:15 PMPediatrix Medical Group (MD) To Report Earnings Tomorrow: Here Is What To Expect
Wed 19 Feb 25, 01:09 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 81.37M | 135.23M | 7.15M | -1241.98000M | 368.84M |
| Minority interest | 0.00400M | 0.03M | 0.23M | 0.23M | 0.23M |
| Net income | 66.33M | 130.96M | -9.58000M | -1150.09400M | 268.63M |
| Selling general administrative | 231.40M | 263.36M | 248.95M | 404.64M | 432.38M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 467.03M | 513.24M | 449.32M | 892.00M | 989.51M |
| Reconciled depreciation | 35.64M | 32.15M | 28.44M | 78.86M | 111.28M |
| Ebit | 172.69M | 202.92M | 173.52M | 416.27M | 452.67M |
| Ebitda | 237.36M | 251.80M | 201.96M | 495.13M | 563.95M |
| Depreciation and amortization | 64.67M | 48.88M | 28.44M | 78.86M | 111.28M |
| Non operating income net other | -56.67400M | 15.56M | 19.50M | - | 11.76M |
| Operating income | 172.69M | 202.92M | 173.52M | 416.27M | 445.85M |
| Other operating expenses | 1772.02M | 1693.45M | 1562.02M | 3105.05M | 3201.28M |
| Interest expense | 39.70M | 68.72M | 110.48M | 119.38M | 88.77M |
| Tax provision | 18.81M | 27.24M | 16.73M | -91.88600M | 100.21M |
| Interest income | 34.30M | 53.16M | 90.98M | 105.93M | 76.75M |
| Net interest income | -39.69500M | -68.72200M | -110.48200M | -119.38100M | -88.76900M |
| Extraordinary items | 3.77M | 22.95M | -786.90800M | -347.60800M | 10.02M |
| Non recurring | 27.31M | 22.10M | 73.80M | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 18.81M | 27.24M | 16.73M | -91.88600M | 100.21M |
| Total revenue | 1972.02M | 1911.19M | 1733.95M | 3513.54M | 3647.12M |
| Total operating expenses | 267.03M | 295.50M | 277.39M | 483.50M | 543.66M |
| Cost of revenue | 1504.99M | 1397.95M | 1284.63M | 2621.54M | 2657.62M |
| Total other income expense net | -91.31800M | -67.69000M | -166.37000M | -1658.25400M | 11.76M |
| Discontinued operations | 3.77M | 22.95M | -786.90800M | -1539.91000M | 10.02M |
| Net income from continuing ops | 62.56M | 107.99M | -9.58000M | -1150.09400M | 268.63M |
| Net income applicable to common shares | 66.33M | 130.96M | -796.48800M | -1497.70200M | 268.63M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2347.89M | 2722.55M | 3347.95M | 4145.90M | 5934.91M |
| Intangible assets | 18.49M | 21.57M | 26.64M | 274.41M | 588.31M |
| Earning assets | - | - | - | - | - |
| Other current assets | 28.14M | 51.68M | 78.70M | 45.36M | 56.47M |
| Total liab | 1456.26M | 1825.85M | 2600.23M | 2646.91M | 2847.03M |
| Total stockholder equity | 891.63M | 896.69M | 747.72M | 1499.00M | 3087.88M |
| Deferred long term liab | 33.64M | 41.41M | 61.75M | - | 131.24M |
| Other current liab | 199.96M | -22.17400M | -21.15200M | -23.44700M | 469.13M |
| Common stock | 0.83M | 0.86M | 0.86M | 0.84M | 0.88M |
| Capital stock | 0.83M | 0.86M | 0.86M | 0.84M | 0.88M |
| Retained earnings | -89.06300M | -155.39000M | -286.35400M | 510.21M | 2094.36M |
| Other liab | 348.68M | 365.91M | 372.37M | 330.21M | 372.55M |
| Good will | 1834.48M | 1794.96M | 1715.99M | 3057.16M | 4689.19M |
| Other assets | 229.10M | 219.37M | 217.80M | 1776.87M | 777.16M |
| Cash | 9.82M | 387.39M | 1123.84M | 112.77M | 36.74M |
| Cash and equivalents | 9.82M | 387.39M | 1123.84M | 112.77M | 25.49M |
| Total current liabilities | 374.23M | 394.12M | 423.16M | 511.87M | 469.34M |
| Current deferred revenue | 105.92M | - | - | - | -469.38700M |
| Net debt | 743.74M | 678.44M | 680.87M | 1707.98M | 1937.79M |
| Short term debt | 36.49M | 22.17M | 21.15M | 23.45M | 0.25M |
| Short long term debt | 14.90M | - | - | - | - |
| Short long term debt total | 753.57M | 1065.83M | 1804.71M | 1820.75M | 1974.53M |
| Other stockholder equity | 983.60M | 1049.90M | 1029.68M | 987.94M | 1200.46M |
| Property plant equipment | 73.29M | 70.15M | 76.19M | 129.09M | 133.04M |
| Total current assets | 334.75M | 740.85M | 1549.35M | 657.00M | 657.41M |
| Long term investments | 93.24M | 99.72M | - | 74.51M | 69.70M |
| Net tangible assets | 891.63M | 896.49M | -757.12500M | -9.44100M | -1883.42300M |
| Short term investments | 93.24M | 99.72M | 104.87M | 74.51M | 21.92M |
| Net receivables | 296.79M | 301.77M | 241.93M | 498.87M | 542.27M |
| Long term debt | 636.38M | 1002.26M | 1742.59M | 1730.24M | 1974.28M |
| Inventory | - | - | - | - | - |
| Accounts payable | 31.86M | 394.12M | 423.16M | 511.87M | 469.34M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 0.20M | 0.23M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -3.73500M | 1.32M | 3.53M | -202.10200M | -207.81600M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 0.83M | 0.86M | 0.86M | 0.84M | 0.88M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | -89.06300M | -155.39000M | -286.35400M | - | 2094.36M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -105.92500M | -88.34400M | 107.36M | -162.38500M | -333.97600M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2013.14M | 1981.70M | 1798.60M | 3488.90M | 5277.50M |
| Capital lease obligations | 65.80M | 63.57M | 71.02M | 90.51M | 0.25M |
| Long term debt total | 636.38M | 1002.26M | 1742.59M | 1730.30M | 1974.28M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -56.95400M | 1.44M | -28.41300M | 102.45M | -2.17400M |
| Change to liabilities | -1.35400M | -3.47700M | 44.49M | 46.20M | -50.16000M |
| Total cashflows from investing activities | -56.95400M | -53.07300M | 815.51M | 102.45M | -142.76900M |
| Net borrowings | -401.50100M | -759.84800M | -1.67100M | -239.50000M | 120.55M |
| Total cash from financing activities | -487.55400M | -760.11600M | -4.15800M | -393.07000M | -170.61100M |
| Change to operating activities | 18.73M | 30.32M | -26.18600M | -12.55600M | -15.54600M |
| Net income | 62.57M | 108.01M | -9.58000M | -1150.09400M | 268.63M |
| Change in cash | -377.56700M | -736.45200M | 1015.97M | 56.02M | -23.45500M |
| Begin period cash flow | 387.39M | 1123.84M | 107.87M | 56.74M | 80.20M |
| End period cash flow | 9.82M | 387.39M | 1123.84M | 112.77M | 56.74M |
| Total cash from operating activities | 166.94M | 76.74M | 204.62M | 346.64M | 289.93M |
| Issuance of capital stock | 5.40M | 6.85M | 7.01M | 11.26M | 16.26M |
| Depreciation | 35.64M | 32.15M | 28.44M | 78.86M | 111.28M |
| Other cashflows from investing activities | -26.78900M | 84.87M | 872.71M | 152.69M | -91.72700M |
| Dividends paid | - | - | -526.25200M | -1747.30000M | 2223.50M |
| Change to inventory | - | - | -54.88700M | -34.11700M | -66.72800M |
| Change to account receivables | -5.54300M | -72.73100M | 37.94M | 7.85M | -36.59800M |
| Sale purchase of stock | -88.51100M | -4.71900M | -8.49300M | -145.28000M | -302.16000M |
| Other cashflows from financing activities | 1480.73M | 0.41M | 1052.24M | 3475.29M | 4434.65M |
| Change to netincome | 31.38M | -14.16200M | 912.78M | 1813.45M | 3.65M |
| Capital expenditures | 29.71M | 32.25M | 28.79M | 31.88M | 48.87M |
| Change receivables | -5.54300M | -72.73100M | 37.94M | - | -36.59800M |
| Cash flows other operating | 38.72M | 52.84M | -29.70400M | - | -11.45000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -377.56700M | -736.45200M | 1015.97M | - | -23.45500M |
| Change in working capital | 31.83M | -23.35600M | 52.73M | 97.24M | -97.11500M |
| Stock based compensation | 16.13M | 18.97M | 39.04M | 35.35M | 38.70M |
| Other non cash items | 43.55M | -27.79700M | 57.70M | 1462.28M | -7.42400M |
| Free cash flow | 137.23M | 44.49M | 175.83M | 314.76M | 241.06M |
Sector: Healthcare Industry: Medical Care Facilities
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MD Mednax Inc |
-0.33 1.67% | 19.46 | 9.00 | 6.31 | 0.37 | 0.78 | 0.66 | 6.79 |
| HCA HCA Holdings Inc |
-4.7 0.87% | 532.58 | 13.19 | 13.66 | 1.13 | 293.44 | 1.77 | 8.22 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.27 1.96% | 13.48 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| FSNUF Fresenius SE & Co. KGaA |
- -% | 54.35 | 16.76 | 9.62 | 0.42 | 0.79 | 0.78 | 5.31 |
| JDHIY JD Health International Inc |
- -% | 9.08 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services through pediatric subspecialists, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
1301 Concord Terrace, Sunrise, FL, United States, 33323
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark S. Ordan | CEO & Director | 1959 |
| Dr. Roger J. Medel M.D. | Co-Founder & Director | 1947 |
| Mr. C. Marc Richards | Exec. VP & CFO | 1971 |
| Mr. John C. Pepia | Sr. VP & Chief Accounting Officer | 1963 |
| Ms. Mary Ann E. Moore | Exec. VP and Chief Enterprise Risk & Legal Operations Officer | 1960 |
| Dr. James D. Swift M.D. | Exec. VP & Chief Operating Officer | NA |
| Ms. Cheryl M. VanPattan | Sr. VP & Chief Information Officer | NA |
| Mr. Charles W. Lynch C.F.A. | Sr. VP of Fin., Strategy & Investor Relations | NA |
| Ms. Dana Dreher-Rodwell | VP & Chief Compliance Officer | NA |
| Ms. Meghan K. Lublin | Sr. VP, Chief Brand & Communications Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.